Cohort study of COVID-19 Nested within an RCT of Patients with Community Acquired Pneumonia: Disease severity, Management, and Outcomes

  • Funded by Research Council of Norway (RCN), Trond-Mohn Foundation
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $537,350
  • Funder

    Research Council of Norway (RCN), Trond-Mohn Foundation
  • Principle Investigator

    Pending
  • Research Location

    Norway, Europe
  • Lead Research Institution

    UNIVERSITETET I BERGEN
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Diagnostics

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The COVID 19-CAPNOR study brings together a multidisciplinary research team that seeks to conduct research that will contribute to containing COVID-19, optimizing patient management and preparedness to the curre and analogous outbreaks. The Bergen CAPNOR consortium recently received funding from the Research Council of Norway (NORCAP 288718) and co-funding from the Trond Mohn foundation (RESPNOR 815276) to recruit patients hospitalized for community acquired pneumonia (CAP) at the Emergency Department (ED Haukeland University Hospital (HUS), Bergen, into a randomized controlled trial (RCT) to assess the impact of comprehensive ultra-rapid, molecular diagnostics compared to current standard of care on a broad range of clinical outcomes. CAPNOR, comprising a preparatory pilot study and the RCT (n=1390) has received approval from the Regional Ethics Committee (REK; 31935). A limited pilot study (n=100 CAP patients) was successfully completed in February 2020. COVID-19 cannot be distinguished clinically from other pneumonias. We propose to rapidly leverage our knowledge-and-skill base as well as, the established research infrastructure at the ED, HUS (e.g. trained study staff, standardised eCRFs, optimised sampling, molecular diagnostics, biobanking) to include patients with suspected COVID-19 at the start of the epidemic in Norway. The patient-centred, opportunity driven cohort study will contribute to i) understanding natural history, disease severity and susceptibility; ii) identify groups at high risk of serious infection; iii) optimising sampling strategies and triage processes; iv) optimizing patient management; v) optimising virus detection, elucidating compartments of replication and mapping of antibody responses; vi) supporting capacity building, infection prevention and control measures and best practice to protect health care workers.